BiondVax – executive interview

Published on 29 July 2022

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Dr Tamar Ben-Yedidia, BiondVax’s chief science officer, discusses the company’s current strategy, the progress made with its NanoAb pipeline and forthcoming milestones.

Share this with friends and colleagues